HIV/AIDS Drugs NIH
HIV/AIDS drug information, including FDA-approved and investigational medications.
Actived: 7 days ago
Table 7. Dosing Recommendations for Drugs Used to Treat or …
(1 days ago) See the Dosing Recommendations for Anti-TB Drugs table in the Mycobacterium tuberculosis section and Drug-Drug Interactions in the Adult and Adolescent Antiretroviral Guidelines for dosage adjustment based on interactions with ARVs. <30. Consider 50% of dose once daily if toxicity is suspected. Monitor serum concentration and adjust dose as needed.
Table 5. Significant Drug Interactions for Drugs Used to Treat or
(6 days ago) ARV drugs: protease inhibitors boosted with ritonavir, efavirenz, etravirine; Caution advised. Statins: simvastatin, lovastatin, atorvastatin; Statins: Do not co-administer with simvastatin or lovastatin. Avoid use of atorvastatin if possible. Alternative statins such as fluvastatin, rosuvastatin, pravastatin are preferred or discontinue statin
Substance Use Disorders and HIV NIH
(9 days ago) People who inject drugs and who also use benzodiazepines engage in riskier behaviors than people who inject drugs but do not use benzodiazepines; these behaviors may include paying for sex, sharing injection equipment with more people, and performing more frequent injections. 49 A cohort of 2,802 people who injected drugs was followed from 1996
Cabotegravir / Rilpivirine
(Just Now) Cabenuva 600 mg/900 mg Kit. Each kit includes a single-dose vial of cabotegravir extended-release injectable suspension and rilpivirine extended-release injectable suspension. Your healthcare provider will administer Cabenuva as two intramuscular injections ( cabotegravir and rilpirivine ), either one time every month or one time every two months.
Prenatal Care, Antiretroviral Therapy, and HIV Management in …
(7 days ago) Regimens should be constructed using ARV drugs that are recommended for use in pregnancy whenever possible. However, in many cases, the presence of extensive drug resistance may warrant the use of ARV drugs for which there is limited experience in pregnancy; consultation with experts in HIV and pregnancy is recommended in such cases.
Table 11. Antiretroviral Drug Use in Pregnant People with HIV
(Just Now) Nucleoside analogue drugs require three intracellular phosphorylation steps to form the triphosphate nucleoside, which is the active drug moiety. The nucleotide analogue tenofovir contains a monophosphate component attached to the adenine base and requires only two phosphorylation steps to form the active moiety. Abacavir (ABC)
Coformulated and Copackaged Antiretroviral Regimens NIH
(3 days ago) Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs included in these products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects.
Drug Interactions between Non-Nucleoside Reverse Transcriptase
(1 days ago) For information regarding interactions between NNRTIs and other ARV drugs, including dosing recommendations, refer to Tables 24c, 25a, and 25b. Recommendations for managing a particular drug interaction may differ, depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or if a new concomitant
Table 9. Advantages and Disadvantages of Antiretroviral
(8 days ago) Oral absorption of DTG can be reduced by simultaneous administration with drugs containing polyvalent cations (e.g., Al-, Ca-, or Mg-containing antacids or supplements or multivitamin tablets with minerals). See dosing recommendations in Table 24d. Inhibits renal tubular secretion of Cr and can increase serum Cr without affecting glomerular
Drug Interactions between Integrase Inhibitors and Other Drugs
(7 days ago) For information regarding interactions between INSTIs and other ARV drugs, including dosing recommendations, refer to Tables 24c, 25a, and 25b. Recommendations for managing a particular drug interaction may differ, depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or whether a new concomitant
Initiation of Antiretroviral Therapy NIH
(5 days ago) Drug interactions should be considered when selecting ART, as there is the potential for significant interactions between chemotherapeutic agents and some antiretroviral drugs (particularly some ritonavir-boosted or cobicistat-boosted regimens). Evidence Supporting the Benefits of Antiretroviral Therapy in Preventing Morbidity and Mortality
What's New in the Guidelines
(2 days ago) Virologic Failure. For patients with virologic failure, the Panel’s recommendation of “A new regimen should include at least two, and preferably three, fully active agents (AI) ” has been changed to “A new regimen can include two fully active drugs if at least one with a high resistance barrier is included (e.g., DTG or boosted
Mycobacterium avium Complex Disease NIH
(8 days ago) Organisms of the Mycobacterium avium complex (MAC) are ubiquitous in the environment. 1-6 In the era prior to the availability of effective antiretroviral therapy (ART), M. avium was the etiologic agent in >95% of people living with HIV with advanced immunosuppression who acquired disseminated MAC disease. 4,7-12 Recent studies conducted using
Table 7. Antiretroviral Regimen Considerations for Initial Therapy
(2 days ago) The Following ARV Drugs Have Been Associated with Dyslipidemia: PI/r or PI/c; EFV; EVG/c; BIC, DOR, DTG, RAL, and RPV have fewer lipid effects. TDF lowers lipids; therefore, switching from TDF to TAF is associated with increased lipids. TDF has been associated with lower lipid levels than ABC or TAF.
Capsid Inhibitor(s) NIH
(8 days ago) Capsid inhibitors are a class of drugs that interfere with HIV capsid, a protein shell that protects HIV's genetic material and enzymes needed for replication. Capsid inhibitors can disrupt HIV capsid during multiple stages of the viral life cycle. Currently, capsid inhibitors are still under clinical investigation, and there are no capsid inhibitors approved by the U.S. Food and Drug
Integrase Strand Transfer Inhibitor–Based Regimens NIH
(7 days ago) Summary. Four integrase strand transfer inhibitors (INSTIs)—bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), and raltegravir (RAL)—are approved for use in antiretroviral therapy (ART)-naive patients with HIV. Cabotegravir (CAB) is a new INSTI that is approved to be used with rilpivirine (RPV) as part of a long-acting injectable
Antiretroviral medication Dolutegravir (DTG, Tivicay, Tivicay PD
(9 days ago) Drug Interactions. Additional information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker.. Metabolism: Dolutegravir (DTG) is a uridine diphosphate glucuronyl transferase (UGT) 1A and cytochrome P450 (CYP) 3A substrate and may require dose adjustments when administered with UGT1A-modulating or CYP3A-modulating
Antiretroviral medication Tenofovir Alafenamide (TAF, Vemlidy) NIH
(9 days ago) Additional information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker. Metabolism: Tenofovir alafenamide (TAF) is a substrate of the adenosine triphosphate-dependent transporters P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP).
Drug Interactions between Protease Inhibitors and Other Drugs NIH
(6 days ago) For information regarding interactions between PIs and other ARV drugs, including dosing recommendations, refer to Tables 24c, 25a, and 25b. Recommendations for managing a particular drug interaction may differ depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or whether a new concomitant
Overview of management of anti-HIV medication toxicity or
(7 days ago) The AEs caused by ARV drugs can vary from mild, more common symptoms (e.g., gastrointestinal intolerance, fatigue) to infrequent but severe and life-threatening, illness. Drug-related toxicity can be acute (i.e., occurring soon after a drug has been administered), subacute (i.e., occurring within 1 day to 2 days after administration), or late
Antiretroviral medication Doravirine (DOR, Pifeltro) NIH
(7 days ago) Doravirine (DOR) is a cytochrome P450 (CYP) 3A substrate that is associated with several important drug interactions with drugs that are strong CYP3A enzyme inducers. Coadministration with these drugs may cause significant decreases in DOR plasma concentrations and potential decreases in efficacy, which can lead to the development of resistance.
Antiretroviral medication Efavirenz (EFV, Sustiva) NIH
(6 days ago) Drug Interactions. Additional information about drug interactions is available in the Adult and Adolescent Antiretroviral Guidelines and the HIV Drug Interaction Checker.. Metabolism: Coadministration of efavirenz (EFV) with drugs that are primarily metabolized by cytochrome P450 (CYP) 2C9, CYP2C19, CYP2B6, or CYP3A isozymes may result in altered plasma concentrations of the coadministered drugs.
Drug Interactions between CCR5 Antagonist and Other Drugs NIH
(2 days ago) The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. In cases where an interacting drug needs to be replaced with an alternative, providers should exercise their clinical judgement to select the most appropriate alternative medication to use.
Talaromycosis (Formerly Penicilliosis) NIH
(6 days ago) Talaromycosis is an invasive fungal infection caused by the dimorphic fungus Talaromyces marneffei (formerly Penicillium marneffei) which is endemic in Southeast Asia (in northern Thailand, Vietnam, and Myanmar), East Asia (in southern China, Hong Kong, and Taiwan), and South Asia (in northeastern India) (see the geographic distribution of
Antiretroviral medication abacavir (ABC, Ziagen) NIH
(5 days ago) Initially, the recommended dose for pediatric use was ABC 8 mg/kg twice daily for a total of 16 mg/kg per day. A 2015 FDA review suggested that a total daily dose of ABC 600 mg could be used safely in a person weighing 25 kg (i.e., ABC 24 mg/kg per day, a 50% increase from the …
Antiretroviral medication Atazanavir (ATV, Reyataz) NIH
(7 days ago) Atazanavir/cobicistat (ATV/c) 300 mg/150 mg once daily with food, administered as single agents simultaneously or as the coformulated drug Evotaz. e. Both ATV/r and ATV/c must be used in combination with other antiretroviral drugs. [Evotaz] Atazanavir/Cobicistat. Child and Adolescent (Weighing ≥35 kg) and Adult Dose.
Extensively Drug-Resistant Tuberculosis (XDR-TB) NIH
(7 days ago) A relatively rare type of multidrug-resistant tuberculosis (MDR-TB). Extensively drug-resistant tuberculosis (XDR-TB) occurs when a Mycobacterium tuberculosis strain becomes resistant to the first-line anti-TB drugs isoniazid and rifampin, plus any fluoroquinolone and at least one of the three second-line injectable drugs. XDR-TB progresses more rapidly and is more severe in people who
Hepatitis B Virus NIH
(6 days ago) Hepatitis B virus (HBV) is the leading cause of chronic liver disease worldwide. 1-5 Globally and in North America, approximately 10% of patients with HIV infection have evidence of chronic HBV infection. 6-8. In countries with a low prevalence of endemic chronic HBV infection, the virus is transmitted primarily through sexual contact and